Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

E-6087

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors.
Anti-inflammatory efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) has been related to their properties as inhibitors… Expand
2009
2009
COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.
Cyclooxygenase 2 (COX-2) inhibitors have been shown to enhance tumor's response to radiation in several animal models. The strong… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2004
2004
Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: Validation and pharmacokinetic application.
E-6087 is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2. Because E-6087 has a chiral… Expand
2002
2002
Enantioseparation of novel COX‐2 anti‐ inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems
A capillary electrophoresis method was developed for the enantioseparation of three novel cyclooxygenase‐2 (COX‐2) inhibitor… Expand
2001
2001
Pharmacokinetics of E‐6087, a new anti‐inflammatory agent, in rats and dogs
The pharmacokinetics of E‐6087, a newly developed cyclooxygenase‐2 inhibitor, was studied in rats and dogs after single oral and… Expand
2001
2001
Development and validation of two chromatographic methods for the quantification of E-6087 and one of its metabolites, E-6132, in rat plasma.
E-6087 is a nonsteroidal anti-inflammatory compound under development that selectively inhibits cyclooxygenase-2. In vitro… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE